$AIDX News

20/20 Biolabs' OneTest Multi-Cancer Early Detection Blood Test Selected As Part Of Firefighter Cancer Screening Initiative For State Of Vermont In Partnership With National Diagnostic Services

20/20 Biolabs Q1 EPS $(0.28) Misses $(0.10) Estimate, Sales $353.375K Miss $779.000K Estimate

20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026

20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina

20/20 BioLabs Strikes Agreement With University Of South Carolina for Commercialization of Patented Algorithm To Evaluate Changes In Prostate-Specific Antigen Levels

Maxim Group Initiates Coverage On 20/20 Biolabs with Buy Rating, Announces Price Target of $5

HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference

20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform

20/20 BioLabs Says Its OneTest For Cancer Is Now Available Through Evexia Diagnostics Platform

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

20/20 Biolabs FY EPS $(0.76) Up From $(1.16) YoY, Sales $2.045M Up From $1.752M YoY

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test

20/20 BioLabs Secures $520K MDH Grant To Deploy OneTest MCED Blood Test Across Maryland Fire Departments

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

What's Going On With 20/20 Biolabs Stock?

20/20 Biolabs shares are trading lower after the company announced it entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare, under which ROKIT will reimburse the company for one-third of expenses in exchange for a running royalty on net sales of the combined product.

20/20 Biolabs shares are trading lower after the company announced it entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare, under which ROKIT will reimburse the company for one-third of expenses in exchange for a running royalty on net sales of the combined product.

20/20 BioLabs Partners With ROKIT To Add AI-Driven Kidney Disease Risk And Biomarker Insights To Longevity Platform

HEALWELL AI Delivers Record Revenue and First Year of Positive Adjusted EBITDA as Global AI Platform Strategy Takes Hold

20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies